Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 373 of 5804
-
Frozen testicle tissue may help cancer survivors become dads
Disease control Recruiting nowThis is a pilot clinical trial to evaluate the feasibility and outcome of autologous transplantation of immature testicular tissue cryopreserved during childhood as a method of fertility preservation for prepubertal boys in case of gonadotoxic therapies. Freezing of immature tes…
Phase: NA • Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for elderly myeloma patients: talquetamab trial opens
Disease control Recruiting nowInduction therapy approaches in recent years have evolved, now utilizing triple or quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients achieve longer remissions…
Phase: PHASE2 • Sponsor: Larysa Sanchez • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New heart device aims to cut hospital stays and deaths in heart failure patients
Disease control Recruiting nowThe purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in Medicare-eligible patients with heart failure who …
Sponsor: Impulse Dynamics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy takes aim at Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug shows promise in shrinking head and neck tumors before surgery
Disease control Recruiting nowThis phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow a…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Triple threat: new Pre-Surgery combo targets stomach cancer
Disease control Recruiting nowThe purpose of this study is to investigate the safety and efficacy of HFRT plus neoadjuvant ICT in locally advanced resectable GEJA.
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for advanced colon cancer: experimental drug combo enters phase 3 trial
Disease control Recruiting nowA Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(H…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New cocktail aims to shrink tough colorectal tumors
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug duo aims to outsmart resistant breast cancer
Disease control Recruiting nowThe goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor an…
Phase: PHASE1, PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could less radiation be just as good for nasopharyngeal cancer?
Disease control Recruiting nowTo evaluate the locoregional control, survival rate, toxicity, and quality of life in patients with nasopharyngeal carcinoma treated with reduced prophylactic irradiation doses to the Low-Risk Clinical Target Volume (CTV).
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New vaccine aims to boost immune system against advanced breast cancer
Disease control Recruiting nowThis phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with hormone receptor (HR)-positive, HER2-negative breast…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Poop pills may revive immunotherapy in lung cancer patients
Disease control Recruiting nowThe goal of IMMUNOLIFE2 is to overcome primary resistance to immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab used alone or in combination with chemotherapy, observed in patients with advanced non-small cell lung cancer (NSCLC) following antibiotic exposure…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New weekly injection could help shed pounds without diabetes
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug duo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase II trial tests how well pirtobrutinib and mosunetuzumab work in treating patients with grade 1-3a follicular lymphoma (FL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pirtobrutinib, a type of…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for ruptured liver cancer: drug combo aims to stop recurrence
Disease control Recruiting nowPrimary liver cancer-particularly hepatocellular carcinoma (HCC)-remains a major health burden in China, characterized by high incidence and mortality rates and poor 5-year survival. Spontaneous rupture of HCC (SRHCC), although a relatively uncommon complication, is associated wi…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contai…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Putting patients in the Driver's seat: can choice improve HIV treatment success?
Disease control Recruiting nowRepeat and prolonged treatment interruption (TI) is common and the major threat to HIV epidemic control in eastern and southern Africa. The proposed project will test an innovative long-term dynamic choice intervention for ART clients experiencing TI in Malawi. Findings will prov…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New triple-drug attack shows promise for hard-to-treat ovarian cancer
Disease control Recruiting nowOvarian cancer is one of the most common gynecologic malignancies, with considerable histologic heterogeneity; more than 90 % of cases are epithelial ovarian cancers. Because no reliable tools exist for early detection, approximately 70 % of patients are diagnosed at an advanced …
Phase: PHASE2 • Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take on kidney disease in early trial
Disease control Recruiting nowA single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
AI reads tumor slides to forecast cancer spread
Knowledge-focused Recruiting nowThe goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer. The main question it aims to answer is: Can a multimodal AI model, trained on routinely ava…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC